Background: Breast carcinoma is the most common malignancy among women worldwide and exhibits remarkable morphological diversity. Histological variants differ significantly in biological behavior, prognosis, molecular profile, and therapeutic response. Accurate identification of these variants is essential for individualized patient management. Clinicopathological correlation helps predict disease progression and optimize treatment strategies.

Objective: To evaluate the morphological variants of breast carcinoma and correlate their histopathological characteristics with clinicopathological parameters including patient age, tumor size, histological grade, lymph node involvement, hormone receptor status, molecular subtype, and clinical outcome.

Materials and Methods: A prospective observational study was conducted on 180 surgically resected breast carcinoma specimens over a two-year period. Histopathological examination was performed using Hematoxylin and Eosin staining according to WHO classification. Tumors were graded using the Nottingham Histological Score. Immunohistochemistry for Estrogen Receptor (ER), Progesterone Receptor (PR), HER2/neu, and Ki-67 proliferation index was performed. Clinicopathological variables were statistically analyzed.

Results: Invasive carcinoma of no special type (NST) accounted for 74.4% of cases followed by invasive lobular carcinoma (9.4%), mucinous carcinoma (4.4%), medullary carcinoma (3.9%), tubular carcinoma (2.8%), papillary carcinoma (2.2%), metaplastic carcinoma (1.7%), and other rare variants (1.2%). Higher-grade tumors demonstrated increased lymphovascular invasion, lymph node metastasis, elevated Ki-67 index, and triple-negative phenotype. Special histological variants such as tubular and mucinous carcinoma exhibited significantly better prognostic features.

Conclusion: Histological subtype remains one of the strongest prognostic indicators in breast carcinoma. Comprehensive clinicopathological evaluation integrated with immunohistochemistry enables accurate diagnosis, prognostic stratification, and personalized therapeutic planning.